- Adj. EBIT better but OCF down in Q3 - Transition in progress - Adj.
- Minor estimate changes - Solid profitability ahead as growth conditions stall - EV/ARR 1.
Förvaltningsresultat ökade i perioden med 21% drivet av förvärvet av grannfastigheten i Poznan i jun...
Redeye sees another quarter where AroCell delivers sales relatively in line with our estimates and c...
Tredje kvartalet 2024 uppvisade en något svagare omsättningstillväxt än vi räknat med och vi har val...
Dovre’s EUR 2.4m EBIT was soft relative to our estimate despite the high top line, but in our view v...
Consti's net sales in Q3 amounted to EUR 86.0m, slightly above our estimates (Evli est.
Vaisala’s Q3 fell short of our estimates for both net sales and profitability.
LapWall revised its 2024 financial guidance range yesterday, the positive update in terms of profita...
Redeye retains its positive view of Avensia following a solid Q3 report with a healthy underlying ma...
- FY sales SEK 2.1-2.2bn (prev. 2.4bn), EBITA margin 6% (prev.
- Q3 sales -6% below our ests. at SEK 202m, for -8% org.
- Sales -4% and EBIT -1% vs. ABGSCe - Organic growth of +1%, below ABGSCe +5% - Likely to see margin...
- Pre-announces Q3 sales 5% below ABGSCe... - ... and ~7% below on adj.
- 9% organic growth (ABG 9%) and EBITA -6% vs ABG - Positive development in all markets, Systems gre...
- Q3 pre-announced, outlook encouraging but dependent on OEMs - Consensus could lower '24e-'25e EBIT...
- Q3 report out on 8 November, 07:00 CET - '24e-'26 sales and EBIT ests.
- Sales -6%, adj. EBITA +5% vs cons in Q3 - Strong performance in product companies behind solid mar...
- Sales -2%, adj. EBITA +1% vs. cons, +3% org. growth - Consensus to raise '24e-'25e EBITA by 1-3% -...
- Mixed Q3, but with signs of improvements - We revise EBITDA down by 1.
